| Identification | Back Directory | [Name]
dBET1 | [CAS]
1799711-21-9 | [Synonyms]
dBET1
CS-2706
DBET1;DBET-1 ;DBET 1
6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetamide, 4-(4-chlorophenyl)-N-[4-[[2-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]oxy]acetyl]amino]butyl]-2,3,9-trimethyl-, (6S)- | [Molecular Formula]
C38H37ClN8O7S | [MDL Number]
MFCD31544503 | [MOL File]
1799711-21-9.mol | [Molecular Weight]
785.27 |
| Chemical Properties | Back Directory | [Melting point ]
186 - 187°C | [density ]
1.55±0.1 g/cm3(Predicted) | [storage temp. ]
Hygroscopic, -20°C Freezer, Under inert atmosphere | [solubility ]
DMSO (Slightly), Methanol (Slightly) | [form ]
Solid | [pka]
10.68±0.40(Predicted) | [color ]
Pale Yellow | [Stability:]
Hygroscopic |
| Hazard Information | Back Directory | [Description]
dBET1 is a PROTAC compound comprised of BET bromodomain antagonist (+)-JQ1 linked to a cereblon E3 ubiquitin ligase ligand. | [Uses]
dBET1 induces highly selective cereblon-dependent BET protein degradation in vitro and in vivo as well as delays leukemia progression in mice. | [storage]
Store at -20°C |
|
|